Researchers have discovered a new early-onset movement disorder associated with mutations in the ACBD6 gene, and several symptoms are similar to those observed in Parkinson’s disease. Genetic sequencing across more than two dozen unrelated families uncovered disease-causing mutations in the gene that were linked to a distinct neurodevelopmental disease that has…
IntelGenx has won approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 trial on Montelukast Versafilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The Phase 2 MONTPARK multicenter study will investigate the effectiveness of oral high-dose Montelukast on the progression…
The Parkinson’s Foundation is calling for applications for $1 million in 2024 community grants, with funding supporting health, wellness, and educational programs that address unmet needs in local Parkinson’s disease communities in the U.S. The application deadline is Jan. 31; recipients will be announced in July. The…
Positron emission tomography (PET) scans of the heart can help to identify people, known to be at risk for Parkinson’s disease or Lewy body dementia, up to seven years before they go on to develop these disorders, a small study suggests. In the National Institutes of Health (NIH)…
Cerevance has dosed the first participant in a Phase 2 clinical trial evaluating the safety and efficacy of its investigational oral therapy CVN424 for Parkinson’s disease. The ASCEND trial (NCT06006247) will explore the safety and efficacy of CVN424 as a single therapy in people with early-stage…
Mission Therapeutics’ experimental oral therapy MTX325, for Parkinson’s disease, spurred brain cells in mice to clear damaged mitochondria — the powerhouses of the cells — ultimately protecting them from death caused by toxic alpha-synuclein protein clumping. That’s according to the findings of a new study using a Parkinson’s…
A pilot trial into whether deep brain stimulation based on noninvasive neuromodulation of a lower leg nerve can safely and effectively ease symptoms of Parkinson’s disease and essential tremor is fully enrolled, Stimvia, its developer, announced. The 24 patients in the study (NCT06036368) will use the company’s…
An implanted device that delivers electrical stimulation to nerve cells in the spine helped reduce gait freezing in a man with Parkinson’s disease, improving his ability to walk. Gait freezing occurs when a person stops walking without meaning to, which can lead to falls. The device’s development was described…
UB-312, an experimental vaccine being developed for Parkinson’s disease by Vaxxinity, induced the production of antibodies targeting alpha-synuclein and slowed protein clumping in patients’ cerebrospinal fluid (CSF), the fluid that surrounds the brain and the spinal cord. The vaccine is designed to stimulate a patient’s immune system…
Toxic clumping of the alpha-synuclein protein, a hallmark of Parkinson’s disease, may lead to a calcium imbalance in which the mineral builds up to harmful levels in neurons early in the course of the neurodegenerative condition, according to a study in mouse and human cells. Single molecules of alpha-synuclein…
Get regular updates to your inbox.